Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy.

Front Oncol · 2022 · PMC9733669 · PMID 36505870

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an obvious trendno p-value reported

Moreover, the expression of PD-L1 in disease progression (PD), stable disease (SD) and partial response (PR) patients did not show an obvious trend of gradual increase ( 26 ).

also in 1,006 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.